Innovació
Presentació dels Hospitals
Visita'ns
Agenda
Col·labora

DIBIOMEC. Grup de recerca en biomarcadors de malalties i mecanismes moleculars

NUTRICIÓ I METABOLISME
BIOMARCADORS TWEAK/FN14 MICRORNAS CÀNCER
OBJECTIUS

El grup Disease Biomarker and Molecular Mechanism (DIBIOMEC) està interessat en la recerca de biomarcadors per al diagnòstic i/o pronòstic de malalties relacionades amb la inflamació. La recerca de biomarcadors està basa principalment en microRNAs associats a exosomes i aprofundim en els seus gens-diana relacionats per trobar possibles dianes terapèutiques. El nostre grup també té una sòlida formació en l’estudi de l’eix inflamatori format per la citocina TWEAK i el seu receptor Fn14 en entorns inflamatoris de baix grau com l’obesitat o microambients inflamatoris com el càncer o l’artritis reumatoide. La nostra recerca es propera als pacients, i el nostre objectiu és traslladar els nostres descobriments a la clínica. Per això, comptem amb un grup multidisciplinari, que associa uròlegs, patòlegs i científics bàsics que fan preguntes clíniques rellevants que necessiten respostes biològiques. El nostre flux de treball contempla la informació obtinguda dels pacients que es tradueix a experiments in vitro per respondre aquestes preguntes. Aquest disseny s’utilitza per trobar possibles biomarcadors per al diagnòstic i/o pronòstic clínic i per desxifrar el seu mecanisme d’acció molecular.

RESPONSABLES

  • Matilde Rodríguez Chacón

  • Línies
  • Membres
  • Publicacions
  • Projectes
  • Transferència
  • Contacte

a) Eix TWEAK/Fn14 com a biomarcador de diagnòstic i pronòstic de malalties inflamatories. Estudi dels seus mecanismes d’acció

b) Estudi del eix TWEAK/Fn14 en context inflamatori del càncer de pròstata. Anàlisis del microambient inflamatori i metabòlic

c) Exovesicules i teixit adipós peritumoral

    Año

    A Serum Biomarker Panel of exomiR-451a, exomiR-25-3p and Soluble TWEAK for Early Diagnosis of Rheumatoid Arthritis.

    Rodríguez-Muguruza S, Altuna-Coy A, Castro-Oreiro S, Poveda-Elices MJ, Fontova-Garrofé R, Chacón MR.Front Immunol. 2021 Nov 15;12:790880. doi: 10.3389/fimmu.2021.790880. eCollection 2021.PMID: 34868079

    Serum Levels of the Cytokine TWEAK Are Associated with Metabolic Status in Patients with Prostate Cancer and Modulate Cancer Cell Lipid Metabolism In Vitro.

    Altuna-Coy A, Ruiz-Plazas X, Alves-Santiago M, Segarra-Tomás J, Chacón MR. Cancers (Basel). 2021 Sep 18;13(18):4688. doi: 10.3390/cancers13184688.

    PMID: 34572917

    Liquid Biopsy-Based Exo-oncomiRNAs Can Predict Prostate Cancer Aggressiveness.

    Ruiz-Plazas X, Altuna-Coy A, Alves-Santiago M, Vila-Barja J, García-Fontgivell JF, Martínez-González S, Segarra-Tomás J, Chacón MR.

    Cancers (Basel). 2021 Jan 11;13(2):250. doi: 10.3390/cancers13020250.

    PMID: 33440913

    Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients

    Fernández-Díaz C, Castañeda S, Melero-González RB, Ortiz-Sanjuán F, Juan-Mas A, Carrasco-Cubero C, Casafont-Solé I, Olivé A, Rodríguez-Muguruza S et al.
    Rheumatology (Oxford). 2020 Dec 1;59(12):3906-3916.
    DOI: 10.1093/rheumatology/keaa621

     

    Predictors of fatigue and persistent fatigue in early rheumatoid arthritis: a longitudinal observational study, data from the ESPOIR cohort

    Rodríguez-Muguruza S, Combe B, Guillemin F, Fautrel B, Olive A, Marsal S, Valero O, Rincheval N, Lukas C.
    Scand J Rheumatol. 2020 Jul;49(4):259-266.
    DOI: 10.1080/03009742.2020.1726449

     

    Biofluid quantification of TWEAK/Fn14 axis in combination with a selected biomarker panel improves assessment of prostate cancer aggressiveness.

    Ruiz-Plazas X, Rodríguez-Gallego E, Alves M, Altuna-Coy A, Lozano-Bartolomé J, Portero-Otin M, García-Fontgivell JF, Martínez-González S, Segarra J, Chacón MR.J Transl Med. 2019 Sep 9;17(1):307. doi: 10.1186/s12967-019-2053-6.

    Biofluid quantification of TWEAK/Fn14 axis in combination with a selected biomarker panel improves assessment of prostate cancer aggressiveness.

    Ruiz-Plazas X, Rodríguez-Gallego E, Alves M, Altuna-Coy A, Lozano-Bartolomé J, Portero- Otin M, García-Fontgivell JF, Martínez-González S, Segarra J*, Chacón MR*.Biofluid
    J Transl Med. 2019 Sep 9;17(1):307. doi: 10.1186/s12967-019-2053-6
    IF: 4.098 Q1 Citations (WOS): 0

    Altered Expression of miR-181a-5p and miR-23a-3p Is Associated With Obesity and TNFα- Induced Insulin Resistance.

    Lozano-Bartolomé J, Llauradó G, Portero-Otin M, Altuna-Coy A, Rojo-Martínez G, Vendrell J, Jorba R, Rodríguez-Gallego E, Chacón MR*.
    J Clin Endocrinol Metab. 2018 Apr 1;103(4):1447-1458. doi: 10.1210/jc.2017-01909.
    IF: 5.605 Q1 Citations (WOS): 9

    GNIP1 E3 ubiquitin ligase is a novel player in regulating glycogen metabolism in skeletal muscle.

    Montori-Grau M, Pedreira-Casahuga R, Boyer-Díaz Z, Lassot I, García-Martínez C, Orozco A, Cebrià J, Osorio-Conles O, Chacón MR, Vendrell J, Vázquez-Carrera M, Desagher S, Jiménez-Chillarón JC, Gómez-Foix AM.
    Metabolism. 2018 Jun;83:177-187. doi: 10.1016/j.metabol.2018.02.005. Epub 2018 Feb 18.
    IF: 6.513 Q1 Citations (WOS): 3

    Iron deficiency is associated with Hypothyroxinemia and Hypotriiodothyroninemia in the Spanish Januaryal adult population: Di@bet.es study.

    Maldonado-Araque C, Valdés S, Lago-Sampedro A, Lillo-Muñoz JA, Garcia-Fuentes E, Perez- Valero V, Gutierrez-Repiso C, Goday A, Urrutia I, Peláez L, Calle-Pascual A, Castaño L, Castell C, Delgado E, Menendez E, Franch-Nadal J, Gaztambide S, Girbés J, Ortega E, Vendrell J, Chacón MR, Chaves FJ, Soriguer F, Rojo-Martínez G.
    Sci Rep. 2018 Apr 26;8(1):6571. doi: 10.1038/s41598-018-24352-9.
    IF: 4.011 Q1 Citations (WOS): 2

    Population-Based National Prevalence of Thyroid Dysfunction in Spain and Associated Factors: Di@bet.es Study.

    Valdés S, Maldonado-Araque C, Lago-Sampedro A, Lillo JA, Garcia-Fuentes E, Perez-Valero V, Gutierrez-Repiso C, Ocon-Sanchez P, Goday A, Urrutia I, Peláez L, Calle-Pascual A, Bordiú E, Castaño L, Castell C, Delgado E, Menendez E, Franch J, Gaztambide S, Girbés J, Ortega E, Lopez-Alba A, Chaves FJ, Vendrell J, Chacón MR, Soriguer F, Rojo-Martínez G.
    Thyroid. 2017 Feb;27(2):156-166. doi: 10.1089/thy.2016.0353. Epub 2017 Jan 4.
    IF: 7.557 Q1/D1 Citations (WOS): 14

    Reference values for TSH may be inadequate to define hypothyroidism in persons with morbid obesity: Di@bet.es study

    Valdés S, Maldonado-Araque C, Lago-Sampedro A, Lillo-Muñoz JA, Garcia-Fuentes E, Perez-ValeroV, Gutiérrez-Repiso C, Garcia-Escobar E, Goday A, Urrutia I, Peláez L, Calle-Pascual A, Bordiú E, Castaño L, Castell C, Delgado E, Menéndez E, Franch-Nadal J, Gaztambide S, Girbés J, Ortega E, Vendrell J, Chacón MR, Javier Chaves F, Soriguer F, Rojo-Martínez G.
    Obesity (Silver Spring). 2017 Apr;25(4):788-793. doi: 10.1002/oby.21796. Epub 2017 Mar 9.
    IF: 4.042 Q1 Citations (WOS): 4

    External validation of sTWEAK as a prognostic noninvasive biomarker for head and neck squamous cell carcinoma.

    Terra X, Gómez D, García-Lorenzo J, Flores JC, Figuerola E, Mora J, Chacón MR, Quer M,
    Camacho M, León X, Avilés-Jurado FX.
    Head Neck. 2016 Apr;38 Suppl 1:E1358-63. doi: 10.1002/hed.24227. Epub 2015 Dec 17.
    IF: 2.760 Q1/D1 Citations (WOS): 5

    Reduced circulating levels of sTWEAK are associated with NAFLD and may affect hepatocyte triglyceride accumulation

    Lozano-Bartolomé J, Llauradó G, Rodriguez MM, Fernandez-Real JM, Garcia-Fontgivell JF,
    Puig J, Maymó-Masip E, Vendrell J, Chacón MR*.
    Int J Obes (Lond). 2016 Sep;40(9):1337-45. doi: 10.1038/ijo.2016.73. Epub 2016 Apr 28.
    IF: 3.873 Q1 Citations (WOS): 6

    Low blood levels of sTWEAK are related to locoregional failure in head and neck cancer

    Avilés-Jurado FX, Terra X, Gómez D, Flores JC, Raventós A, Maymó-Masip E, León X,
    Serrano-Gonzalvo V, Vendrell J, Figuerola E, Chacón MR*.

    Eur Arch Otorhinolaryngol. 2015 Jul;272(7):1733-41. doi: 10.1007/s00405-014-3095-2. Epub
    2014 May 26. IF: 1.627 Q2 Citations (WOS): 7

    Reduced circulating levels of TWEAK are associated with gestational diabetes mellitus

    Simón-Muela I, Llauradó G, Chacón MR, Olona M, Näf S, Maymó-Masip E, Gil P, de la Flor M,Gonzalez Clemente JM, Vendrell J, Megía A.
    Eur J Clin Invest. 2015 Jan;45(1):27-35. doi: 10.1111/eci.12375. IF: 2.687 Q1 Citations
    (WOS): 9

    PPARβ/δ ameliorates fructose-induced insulin resistance in adipocytes by preventing Nrf2 activation

    Barroso E, Rodríguez-Rodríguez R, Chacón MR, Maymó-Masip E, Ferrer L, Salvadó L, Salmerón E, Wabistch M, Palomer X, Vendrell J, Wahli W, Vázquez-Carrera M.
    Biochim Biophys Acta. 2015 May;1852(5):1049-58. doi: 10.1016/j.bbadis.2015.02.010. Epub
    2015 Feb 26. IF: 5.128 Q1 Citations (WOS): 11

    Obesity changes the human gut mycobiome

    Rodríguez MM Pérez D, Javier Chaves F, Esteve E, Marin-Garcia P, Xifra G, Vendrell J, Jové
    M, Pamplona R, Ricart W, Portero-Otin M, Chacón MR*, Fernández Real JM*.
    Sci Rep. 2015 Oct 12;5:14600. doi: 10.1038/srep14600. Erratum in: Sci Rep. 2016;6:21679.
    IF: 5.228 Q1/D1 Citations (WOS): 55

    HIV-1/HAART-Related Lipodystrophy Syndrome (HALS) Is Associated with Decreased Circulating sTWEAK Levels.

    López-Dupla M, Maymó-Masip E, Martínez E, Domingo P, Leal M, Peraire J, Viladés C, Veloso S,Arnedo M, Ferrando-Martínez S, Beltrán-Debón R, Alba V, Gatell JM, Vendrell J, Vidal F, Chacón MR*.
    PLoS One. 2015 Dec 14;10(12):e0144789. doi: 10.1371/journal.pone.0144789. eCollection
    2015. IF: 3.057 Q1 Citations (WOS): 5

    Serum sCD163 levels are associated with type 2 diabetes mellitus and are influenced by coffee and wine consumption: results of the Di@bet.es study.

    Rojo-Martínez G, Maymó-Masip E, Rodríguez MM, Solano E, Goday A, Soriguer F, Valdés S, Chaves FJ, Delgado E, Colomo N, Hernández P, Vendrell J, Chacón MR.
    PLoS One. 2014 Jun 30;9(6):e101250. doi: 10.1371/journal.pone.0101250. eCollection 2014.
    IF: 3.234 Q1 Citations (WOS): 4

    TWEAK prevents TNF-α-induced insulin resistance through PP2A activation in human adipocytes.

    Vázquez-Carballo A, Ceperuelo-Mallafré V, Chacón MR, Maymó-Masip E, Lorenzo M, Porras A, Vendrell J, Fernández-Veledo S.
    Am J Physiol Endocrinol Metab. 2013 Jul 1;305(1):E101-12. doi:10.1152/ajpendo.00589.2012.
    Epub 2013 May 7. IF: 4.088 Q1 Citations (WOS): 20

    Serum sTWEAK concentrations and risk of developing type 2 diabetes in a high cardiovascular risk population: a nested case-control study.

    Díaz-López A, Chacón MR*, Bulló M, Maymó-Masip E, Martínez-González MA, Estruch R, Vendrell J, Basora J, Díez-Espino J, Covas MI, Salas-Salvadó J*.
    J Clin Endocrinol Metab. 2013 Aug;98(8):3482-90. doi: 10.1210/jc.2013-1848.
    Epub 2013 Jun 12. IF: 6.310 Q1 Citations (WOS): 9

    The rise of soluble TWEAK levels in severely obese subjects after bariatric surgery may affect adipocyte-cytokine production induced by TNFα.

    Maymó-Masip E, Fernández-Veledo S, Garcia España A, Vázquez-Carballo A, Tinahones FJ, García-Fuentes E, Garrifo-Sanchez L, Rodriguez Mdel M, Vendrell J, Chacón MR*.
    J Clin Endocrinol Metab. 2013 Aug;98(8):E1323-33. doi: 10.1210/jc.2012-4177. Epub 2013
    Jun 19. IF: 6.310 Q1 Citations (WOS): 17

    TWEAK: A New Player in Obesity and Diabetes.

    Vendrell J, Chacón MR.
    Front Immunol. 2013 Dec 30;4:488. doi: 10.3389/fimmu.2013.00488. Review. Citations
    (WOS): 22

    Reduced circulating sTWEAK levels are associated with metabolic syndrome in elderly individuals at high cardiovascular risk.

    Díaz-López A, Bulló M, Chacón MR*, Estruch R, Vendrell J, Díez-Espino J, Fitó M, Corella D, Salas-Salvadó J*.
    Cardiovasc Diabetol. 2014 Feb 24;13:51. doi: 10.1186/1475-2840-13-51. IF: 4.015 Q1
    Citations (WOS): 9

    Projectes fiançats per entitat publiques o privades

  • Títol del projecte:  Identification of TWEAK regulated Exo-oncomicroRNAs in the crosstalk between peritumoral adipose tissue and prostate cancer cells. Usefulness as biomarkers for diagnosis and prognosis.

    Entitat finançadora: Fondo de Investigación Sanitaria. Instituto de Salud Carlos III. Proyectos de investigación en salud. EXPEDIENT Nº: PI20/00418

    Durada: 2021-2023

    Investigador Principal  (PI): Matilde Rodríguez Chacón Co-PI: Xavier Ruiz Plazas.

  • Títol del Projecte: ExomicroRNAs asociados a artritis reumatoide naïve en biopsia líquida como biomarcadores tempranos de la enfermeda.

    Entitat Finançadora: Societat Catalana de Reumatologia (Beca Lilly)

    Durada: 2020-2022.

    Investigadora Principal (PI):  Samantha Rodriguez Co-IP: Matilde Rodriguez Chacón

     

  • Títol del projecte: Study of TWEAK / CD163 as biomarkers of type 2 diabetes in
    the di @ betes cohort. Local molecular aspects in adipose tissue
    Entitat finançadora:Fondo de Investigación Sanitaria EXPEDIENT Nº: PI 11/00049
    Durada: 2012-2014
    Investigador Principal: Matilde Rodríguez Chacón

  • Títol del projecte: Identification and characterization of microRNAs regulated by
    sTWEAK in the adipocyte and its role in the inflammatory response associated with Insulin
    Resistance. Analysis of its usefulness as biomarkers in the Pizarra and di@bet.es studies.
    Entitat finançadora: Fondo de Investigación Sanitaria EXPEDIENT Nº: PI 14/00465
    Durada: 2015-2018
    Investigador Principal: Matilde Rodríguez Chacón

  • Títol del projecte: Study the TWEAK cytokine and its Fn14 and CD163 receptors
    as potential noninvasive biomarkers in the context of prostate cancer. Relationship with the
    patient’s metabolic status
    Entitat finançadora: Fondo de Investigación Sanitaria EXPEDIENT Nº: PI 17/00877
    Durada: 2018-2020
    Investigador Principal: Matilde Rodríguez Chacón Co- IP: Xavier Ruiz Plazas

  • Títol del projecte: Study of the TWEAK / Fn14 / CD163 axis as a panel of non-
    invasive biomarkers in the diagnosis / prognosis of prostate cancer.
    Entitat finançadora: Fundación Para la Investigación en urologia. Ayuda a la investigación
    Pedro Cifuentes Diaz
    Durada: 2018-2019
    Investigador Principal: Matilde Rodríguez Chacón Co- IP: Xavier Ruiz Plazas

  • Títol del projecte: Analyses of the global kinase activities in adipose tissue to find
    molecular differences resulting from insulin resistance across different clinical phenotypes
    from lean to obese and type 2 diabetic patients. Discovery of new targets for therapy
    EXPEDIENT Nº: (86/C/2016).
    Entitat finançadora: Marató TV3
    Durada: 2017-2019
    Investigador Principal: Joan Vendrell Ortega,
    Tipus de participació: membre del equip

  • Títol del projecte: Identification and functional characterization of microRNAs
    regulated by the TWEAK cytokine in the context of prostate cancer: search for new biological
    markers of diagnosis and prognosis as well as new therapeutic targets
    Entitat finançadora: Fundación Vallformosa. IV Premi Martí Via
    Durada: 2019-2020
    Investigador Principal: Xavier Ruiz-Plazas Co-PI: Matilde Rodriguez Chacón
    TYPE OF PARTICIPATION: Co-PI

  • Title: Estudio la citocina TWEAK y de sus receptores FN14 y CD163 como potenciales biomarcadores no invasivos en el contexto de cáncer próstata. Relación con el estatus metabólico del paciente (PI17/00877).

    Funding entity: Instituto de Salud Carlos III

    Duration: 2018 – 2021

    Principal Investigator: Matilde Rodriguez Chacón

  • Title: 2017 SGR 00032 Suport a grups de recerca (SGR) IISPV validació tècnica – Grup de recerca consolidat.

    Funding entity: Agència de Gestió d’Ajuts Universitaris i de Recerca.

    Duration: 2017 – 2021

    Principal Investigator: Matilde Rodriguez Chacón

  • INVENTORS: Matilde Rodríguez Chacón, Xavier Ruiz Plazas, Josep Segarra Tomás, Joan
    Francesc García Fontgivell, Salomé Martínez González, Javier Lozano Bartolomé.
    TÍTOL: Biomarcadors d’agressivitat de càncer de pròstata
    No: EP18382842.5
    APPLICACIÓ DATA: 22/11/2018
    INSTITUCIÓ: Institut d’Investigació Sanitària Pere Virgili (IISPV)

    Biomarkers of prostate cancer aggressiveness

  • INVENTORS: Matilde Rodríguez Chacón, Xavier Ruiz Plazas, Josep Segarra Tomás, Joan
    Francesc García Fontgivell, Salomé Martínez González, Javier Lozano Bartolomé,
    TÍTOL: Biomarcadors d’agressivitat de càncer de próstata.
    No: PCT.51529
    APPLICACIÓ DATA: 22/11/2019

     

Membres De L’equip

  • Responsable de grup

    • Matilde Rodríguez Chacón

  • Investigador Clínic

    • José Segarra Tomás
    • Joan García Fontgivell
    • Ramón Fontova Garrofé
    • Xavier Ruiz Plazas,
    • Samantha Rodriguez Muguruza

  • Doctorands

    • Antonio Altuna Coy
    • Marta Alves Santiago
    • Silvia Sánchez Martin

Altres grups de Nutrició i Metabolisme

Veure tots